A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2011
10/06/2011	US20110245154 Methods and Compositions for Treating Viral or Virally-Induced Conditions
10/06/2011	US20110245153 Neutralizing Agents for Bacterial Toxins
10/06/2011	US20110245152 Antibiotic antimicrobial agents and methods of their use
10/06/2011	US20110245151 Bacteriocins and Novel Bacterial Strains
10/06/2011	US20110245150 Targets for treatment of chlamydial infections
10/06/2011	US20110245149 Methods to prevent and treat diseases
10/06/2011	US20110245148 Acetic acid and a buffer
10/06/2011	US20110244574 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
10/06/2011	US20110244062 Multiplication of the efficacy of anti-infectious agents by a composition comprising an extract made from dehydrated and partially sodium-free seawater
10/06/2011	US20110244058 Compositions and methods for treatment of pulmonary diseases and conditions
10/06/2011	US20110244049 Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof, and methods for preparing and using same
10/06/2011	US20110244043 Controlled releasing composition
10/06/2011	US20110244041 Plant extract hydrolysates and antibacterial product containing the same
10/06/2011	US20110244039 Absorbable solid compositions for topical treatment of oral mucosal disorders
10/06/2011	US20110244034 Sustained release drug delivery system
10/06/2011	US20110244030 Topical foaming compositon and method of application
10/06/2011	US20110244027 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections
10/06/2011	US20110244025 Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
10/06/2011	US20110244019 Absorbent fabric implant
10/06/2011	US20110244004 Antifungal composition with enhanced bioavailability
10/06/2011	US20110244002 Mesoporous material excipients for poorly aqueous soluble ingredients
10/06/2011	US20110243999 Methods and compositions for the treatment of ocular disorders
10/06/2011	US20110243992 Methods of enhancing the immunogenicity of mycobacteria and compositions for the treatment of cancer, tuberculosis, and fibrosing lung diseases
10/06/2011	US20110243991 Process for production of vaccines
10/06/2011	US20110243990 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
10/06/2011	US20110243989 Idna vaccines and methods for using the same
10/06/2011	US20110243987 Influenza vaccine
10/06/2011	US20110243986 Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
10/06/2011	US20110243980 Methods and systems for o-glycosylating proteins
10/06/2011	US20110243979 Method of Transcutaneous Immunization Using Antigen
10/06/2011	US20110243978 Enterococcus antigens
10/06/2011	US20110243977 Surface proteins of streptococcus pyogenes
10/06/2011	US20110243967 Molecular complexes which modify immune responses
10/06/2011	US20110243962 Therapeutic use of specific ligand in msrv associated diseases
10/06/2011	US20110243960 Methods and compositions for treating p. acnes
10/06/2011	US20110243943 Treatment using relaxin-fusion proteins with extended in vivo half-lives
10/06/2011	US20110243930 Compositions and methods for the treatment of immune related diseases
10/06/2011	US20110243923 Organic compounds
10/06/2011	US20110243916 Modified endolysin ply511
10/06/2011	US20110243915 Antimicrobial agents
10/06/2011	US20110243904 Rna interference target for treating aids
10/06/2011	US20110243896 Anti-viral protection with viruses containing defective genome segments
10/06/2011	US20110243894 Methods of treating hepatitis c virus infection
10/06/2011	US20110243888 Il-29 mutants and uses thereof
10/06/2011	US20110243887 Il-7 fusion proteins
10/06/2011	US20110243886 Compounds and pharmaceutical compositions for the treatment of viral infections
10/06/2011	US20110243881 Biocompatible polymers, process for their preparation and compositions containing them
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	US20110243840 Monoclonal antibodies against orthopoxviruses
10/06/2011	US20110240512 Antibiotic Formulations Providing Reduced Gastrointestinal Side Effects and Clostridium difficile Infection Relapse, and Related Methods
10/06/2011	US20110240012 Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
10/06/2011	CA2799727A1 Polycyclic tetracycline compounds
10/06/2011	CA2795054A1 Compounds and pharmaceutical compositions for the treatment of viral infections
10/06/2011	CA2795038A1 Opioid receptor antagonist (naltrexone) for use in treating herpes zoster disease
10/06/2011	CA2794930A1 Method for inhibiting hiv replication in mammal and human cells
10/06/2011	CA2794671A1 Stereoselective synthesis of phosphorus containing actives
10/06/2011	CA2794669A1 Nucleoside phosphoramidates
10/06/2011	CA2794570A1 Novel combination and use
10/06/2011	CA2794443A1 Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
10/06/2011	CA2794407A1 Humanized anti cxcr4 antibodies for the treatment of cancer
10/06/2011	CA2794377A1 2-oxo-dihydropyridine non-nucleoside reverse transcriptase inhibitors
10/06/2011	CA2793688A1 Monoclonal antibody directed against the p17 protein of hiv, capable of neutralising the binding of p17 to the p17 receptor (p17r)
10/06/2011	CA2792537A1 Influenza virus vaccines and uses thereof
10/05/2011	EP2371966A1 Recombinant lentiviral vector for expression of a Flaviviridae protein and applications thereof as a vaccine
10/05/2011	EP2371945A1 IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
10/05/2011	EP2371863A1 Humanized anti CXCR4 antibodies for the treatment of cancer
10/05/2011	EP2371858A2 Human-Murine chimeric antibodies against respiratory syncytial virus
10/05/2011	EP2371840A1 Novel polypeptide having angiogenesis-inducing activity and antibacterial activity, and use thereof for medical purposes
10/05/2011	EP2371839A1 Peptidomimetic protease inhibitors
10/05/2011	EP2371838A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371837A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371836A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371833A2 10-substituted macrolide antibiotics
10/05/2011	EP2371819A1 New quinoline derivatives, a method for the production and the use thereof for treating microbacterial infections and a pharmaceutical composition based on said derivatives
10/05/2011	EP2371381A2 Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
10/05/2011	EP2371361A1 Methods to mobilize progenitor/stem cells
10/05/2011	EP2370455A2 Virus like particle compositions and methods of use
10/05/2011	EP2370444A1 [4- (1-amino-ethyl) -cyclohexyl]-methyl-amines as antibacterials
10/05/2011	EP2370431A1 1, 2, 4 -oxadiazole derivatives and their therapeutic use
10/05/2011	EP2123271B1 Drug for treatment of influenza
10/05/2011	EP2040724B1 Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
10/05/2011	EP1899352B1 1- [2' , 3' -dideoxy-3' c- (hydroxymethyl) - beta-d-erythro-pentofuranosyl] cytosine derivatives as hiv inhibitors
10/05/2011	EP1787991B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE
10/05/2011	EP1784416B1 Vaccines against aids comprising cmv/r nucleic acid constructs
10/05/2011	EP1463497B1 Treating muscle wasting with selective androgen receptor modulators
10/05/2011	EP1395279B1 Use of neublastin polypeptides for treating neuropathic pain
10/05/2011	EP1377276B1 Timed pulse release composition
10/05/2011	EP1372389B1 Virucidal compositions
10/05/2011	EP1355676B1 Method of protecting therapeutic compositions from host-mediated inactivation
10/05/2011	EP1317262B1 Topically applied hoof treatment composition concentrate
10/05/2011	EP1257248B1 Pharmaceutical composition
10/05/2011	EP1242099B1 Method for inactivating infectious agents in biological fluids
10/05/2011	CN201996869U Enteric particle of enrofloxacin
10/05/2011	CN1990006B Chenopodium ambrosioides extract, preparation thereof, preparation method and use thereof
10/05/2011	CN102209717A Compounds for the treatment of hepatitis c
10/05/2011	CN102209711A Compounds for the treatment of hepatitis c
10/05/2011	CN102209549A Use of ammonium chloride in therapy
10/05/2011	CN102206663A Nucleic acid construct containing full-length genome of human hepatitis C virus and uses
10/05/2011	CN102206660A Engineered protein TAT-VP28 against white spot syndrome virus of shrimp and its preparation and purpose
10/05/2011	CN102206646A Mytilus etilus Hydramacin-1 gene, its recombination protein and preparation method

1 ... 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 ... 1798